---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-23-002118"
form_type: "8-K"
ticker: "STAA"
cik: "0000718937"
company_name: "STAAR SURGICAL CO"
filed_at: "2023-02-21T23:59:59+00:00"
generated_at: "2026-06-19T07:28:17.178966+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# STAAR Surgical Q4 net sales $64M, ICL units +20% YoY; FY2023 ICL sales guidance ~$340M

## Summary
- Q4 net sales $64.0M (+9% YoY); constant currency net sales $67.9M (+15%).
- ICL sales $61.2M (+15% YoY); ICL units +20% YoY; U.S. ICL units +109%.
- FY2022 net sales $284.4M (+23%); ICL sales $269.7M (+27%); ICL units +33%.
- FY2022 GAAP EPS $0.78 vs $0.50 prior year; adjusted EPS $1.22 vs $0.87.
- FY2023 ICL sales guidance ~$340M, representing 26% YoY growth.

## SEC filing metadata
- accession: 0001564590-23-002118
- form_type: 8-K
- ticker: STAA
- cik: 0000718937
- company_name: STAAR SURGICAL CO
- filed_at: 2023-02-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/718937/000156459023002118/0001564590-23-002118-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/718937/000156459023002118/staa-8k_20230221.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-23-002118
- JSON: https://secwatch.observer/filing/0001564590-23-002118.json
- Plain text: https://secwatch.observer/filing/0001564590-23-002118.txt

## Key facts
- Earnings Releases
  STAAR SURGICAL CO reported fourth quarter and fiscal year ended December 30, 2022 results: revenue $64.0 million, net income $0.12 per diluted share, EPS $0.12 per diluted share. Guidance reaffirmed.
  - Period: fourth quarter and fiscal year ended December 30, 2022
  - Revenue: $64.0 million
  - Net income: $0.12 per diluted share
  - EPS: $0.12 per diluted share
  - Guidance: reaffirmed
  - Result: reported results
  source text: of implantable lenses for the eye, today reported financial results for the fourth quarter and fiscal year ended December 30, 2022. Fourth Quarter 2022 Overview • Net Sales of $64.0 Million Up 9% and Constant Currency Net Sales of $67.9 Million Up 15% from Prior Year Quarter • ICL Sales of $61.2 Million Up 15% and Constant Currency ICL Sales of $64.3 Million Up 21%
  evidence_url: https://www.sec.gov/Archives/edgar/data/718937/000156459023002118/0001564590-23-002118-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.